{"version":"1.0","provider_name":"Sickle Cell Disease Association of America Inc.","provider_url":"https:\/\/www.sicklecelldisease.org","author_name":"admin","author_url":"https:\/\/www.sicklecelldisease.org\/author\/admin\/","title":"Temporary Suspension of Clinical Trials - Sickle Cell Disease Association of America Inc.","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"5ejeIeghCY\"><a href=\"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/\">Temporary Suspension of Clinical Trials<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/embed\/#?secret=5ejeIeghCY\" width=\"600\" height=\"338\" title=\"&#8220;Temporary Suspension of Clinical Trials&#8221; &#8212; Sickle Cell Disease Association of America Inc.\" data-secret=\"5ejeIeghCY\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","description":"&nbsp; March 1, 2021 &#8211; The Sickle Cell Disease Association of America\u2019s Medical and Research Advisory Committee (MARAC) is aware of the announcement on February 16, regarding the temporary suspension of bluebird bio clinical trials of LentiGlobin Gene Therapy for Sickle Cell Disease and the pause of all commercial use of bluebird bio European gene [&hellip;]","thumbnail_url":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg"}